^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:5-fluorouracil (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/01/2020
    Excerpt:
    Platinum/5-FU/cetuximab remains the standard therapy for recurrent/metastatic patients with SCCHN not expressing PD-L1 [I, A; ESMO-MCBS v1.1 score: 3]. TPeX is also a treatment option in this population [II, B].
    DOI:
    10.1016/j.annonc.2020.07.011